(Q33860721)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

title

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

author name string

P Poignard

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

R Sabbe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

G R Picchio

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

M Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

R J Gulizia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

H Katinger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

D E Mosier

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

D R Burton

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

language of work or name

English

0 references

publication date

1 April 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

431-438

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10229186%20AND%20SRC:MED&resulttype=core&format=json

Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

5 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Distinct biological and serological properties of human immunodeficiency viruses from the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Human immunodeficiency virus infection of human-PBL-SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Chemokine receptor polymorphism and autologous neutralizing antibody response in long-term HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1074-7613%2800%2980043-6

7 January 2021